$NEO News

Needham Maintains Buy on NeoGenomics, Raises Price Target to $19

NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ...

NeoGenomics, Inc. 2026 Q2 - Results - Earnings Call Presentation

NeoGenomics, Inc. (NEO) Q2 2026 Earnings Call Transcript

NeoGenomics Q2 Earnings Call Highlights

NeoGenomics (NASDAQ:NEO): Quality Stock After Q2 Earnings Beat and Raised Guidance

NeoGenomics’s (NASDAQ:NEO) Q2 CY2026: Beats On Revenue

NeoGenomics Reports Second Quarter 2026 Results

NeoGenomics Raises FY2026 Sales Guidance from $797.000M-$803.000M to $802.000M-$806.000M vs $800.433M Est

NeoGenomics Q2 Adj. EPS $0.05 Beats $0.03 Estimate, Sales $202.000M Beat $196.997M Estimate

NeoGenomics (NEO) Q2 Earnings Report Preview: What To Look For

Benchmark Maintains Buy on NeoGenomics, Raises Price Target to $16

NeoGenomics Announces Settlement of Voluntary Disclosure to OIG-HHS

NeoGenomics Reveals Settlement Of Voluntary Disclosure To OIG-HHS; Co To Pay $9,813,260 Plus Interest At A Rate Of 4.250% Per Annum From January 16, 2026 To Resolve The Matter

NeoGenomics (NEO) Stock Looks Above Fair Value After A 134% Run

Is NeoGenomics (NEO) Undervalued After Its FDA Approved PTEN Test Launch?

PRPO vs. NEO: Which Cancer Diagnostics Stock Is the Better Buy?

NeoGenomics (NEO) Stock Trades Up, Here Is Why

NeoGenomics Launches FDA-Approved PTEN IHC Companion Diagnostic for Prostate Cancer

NeoGenomics Launches PTEN IHC CDx, Immunohistochemistry Companion Diagnostic Test Approved By FDA For Patients With Prostate Adenocarcinoma